Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have earned an average rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.60.

Several brokerages have weighed in on ACRX. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 7th. Oppenheimer began coverage on shares of AcelRx Pharmaceuticals in a research report on Thursday, July 12th. They set a “hold” rating for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $6.00 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 2nd.

In related news, CEO Vincent J. Angotti bought 10,000 shares of the company’s stock in a transaction dated Tuesday, August 7th. The stock was purchased at an average cost of $2.90 per share, with a total value of $29,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Pamela P. Palmer bought 37,000 shares of the company’s stock in a transaction dated Monday, August 6th. The stock was bought at an average cost of $2.75 per share, with a total value of $101,750.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 57,300 shares of company stock valued at $159,552 in the last three months. 25.50% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of AcelRx Pharmaceuticals by 2.7% in the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock worth $2,271,000 after purchasing an additional 17,737 shares during the period. Lincoln Capital Corp purchased a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter worth about $116,000. Northern Trust Corp lifted its position in shares of AcelRx Pharmaceuticals by 60.8% in the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 34,584 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of AcelRx Pharmaceuticals in the 1st quarter worth about $113,000. Finally, Granite Investment Partners LLC purchased a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter worth about $182,000. 8.59% of the stock is owned by hedge funds and other institutional investors.

Shares of ACRX stock traded up $0.05 on Friday, hitting $3.25. 191,720 shares of the company’s stock traded hands, compared to its average volume of 418,834. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.96 and a current ratio of 4.01. AcelRx Pharmaceuticals has a one year low of $1.55 and a one year high of $5.75. The firm has a market cap of $193.92 million, a P/E ratio of -2.95 and a beta of 2.09.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.93 million. analysts forecast that AcelRx Pharmaceuticals will post -0.77 EPS for the current year.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: Technical Analysis

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.